These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 27079434)

  • 21. Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Int J Clin Pharmacol Ther; 2022 Apr; 60(4):176-183. PubMed ID: 34889733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
    Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
    Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
    Hosoya T; Furuno K; Kanda S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):71-79. PubMed ID: 31970593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
    Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
    Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
    Dalbeth N; Saag KG; Palmer WE; Choi HK; Hunt B; MacDonald PA; Thienel U; Gunawardhana L
    Arthritis Rheumatol; 2017 Dec; 69(12):2386-2395. PubMed ID: 28975718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
    Terkeltaub R; Lee J; Min J; Shin S; Saag KG
    Arthritis Rheumatol; 2023 Jul; 75(7):1275-1284. PubMed ID: 36649008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
    Okui D; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
    Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
    Trials; 2014 Jan; 15():26. PubMed ID: 24433285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
    Cicero AFG; Fogacci F; Cincione RI; Tocci G; Borghi C
    Med Princ Pract; 2021; 30(2):122-130. PubMed ID: 33040063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihyperuricemic properties of amflutizole in gout.
    Wortmann RL; Ridolfo AS; Lightfoot RW; Fox IH
    J Rheumatol; 1985 Jun; 12(3):540-3. PubMed ID: 3900392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
    Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
    Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.
    Tanaka A; Nakamura T; Sato E; Node K
    Drugs R D; 2017 Mar; 17(1):97-101. PubMed ID: 28074335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.